Sevelamer hydrochloride for tumor lysis syndrome-related hyperphosphatemia

L. Harsha Prasada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function. Sevelamer, an oral phosphate-binder is used in the treatment of hyperphosphatemia in children and adults on hemodialysis. Case characteristics: Two children with T-cell acute lymphoblastic leukemia who presented with a high tumour load and developed tumour lysis syndrome. Observation: Both children received Rasburicase and Sevelamer hydrochloride. The serum phosphate reduced to normal levels within 24–48 hrs of initiation of sevelamer hydrochloride. Message: Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome.

Original languageEnglish
Pages (from-to)613-615
Number of pages3
JournalIndian Pediatrics
Volume52
Issue number7
DOIs
Publication statusPublished - 31-07-2015
Externally publishedYes

Fingerprint

Tumor Lysis Syndrome
Hyperphosphatemia
Phosphates
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Uric Acid
Tumor Burden
Renal Dialysis
Observation
Calcium
Kidney
Sevelamer
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Harsha Prasada, L. / Sevelamer hydrochloride for tumor lysis syndrome-related hyperphosphatemia. In: Indian Pediatrics. 2015 ; Vol. 52, No. 7. pp. 613-615.
@article{089cfa83087745dcbafe757b2d346e13,
title = "Sevelamer hydrochloride for tumor lysis syndrome-related hyperphosphatemia",
abstract = "Background: Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function. Sevelamer, an oral phosphate-binder is used in the treatment of hyperphosphatemia in children and adults on hemodialysis. Case characteristics: Two children with T-cell acute lymphoblastic leukemia who presented with a high tumour load and developed tumour lysis syndrome. Observation: Both children received Rasburicase and Sevelamer hydrochloride. The serum phosphate reduced to normal levels within 24–48 hrs of initiation of sevelamer hydrochloride. Message: Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome.",
author = "{Harsha Prasada}, L.",
year = "2015",
month = "7",
day = "31",
doi = "10.1007/s13312-015-0686-y",
language = "English",
volume = "52",
pages = "613--615",
journal = "Indian Pediatrics",
issn = "0019-6061",
publisher = "Springer India",
number = "7",

}

Sevelamer hydrochloride for tumor lysis syndrome-related hyperphosphatemia. / Harsha Prasada, L.

In: Indian Pediatrics, Vol. 52, No. 7, 31.07.2015, p. 613-615.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sevelamer hydrochloride for tumor lysis syndrome-related hyperphosphatemia

AU - Harsha Prasada, L.

PY - 2015/7/31

Y1 - 2015/7/31

N2 - Background: Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function. Sevelamer, an oral phosphate-binder is used in the treatment of hyperphosphatemia in children and adults on hemodialysis. Case characteristics: Two children with T-cell acute lymphoblastic leukemia who presented with a high tumour load and developed tumour lysis syndrome. Observation: Both children received Rasburicase and Sevelamer hydrochloride. The serum phosphate reduced to normal levels within 24–48 hrs of initiation of sevelamer hydrochloride. Message: Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome.

AB - Background: Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function. Sevelamer, an oral phosphate-binder is used in the treatment of hyperphosphatemia in children and adults on hemodialysis. Case characteristics: Two children with T-cell acute lymphoblastic leukemia who presented with a high tumour load and developed tumour lysis syndrome. Observation: Both children received Rasburicase and Sevelamer hydrochloride. The serum phosphate reduced to normal levels within 24–48 hrs of initiation of sevelamer hydrochloride. Message: Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome.

UR - http://www.scopus.com/inward/record.url?scp=84938407036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938407036&partnerID=8YFLogxK

U2 - 10.1007/s13312-015-0686-y

DO - 10.1007/s13312-015-0686-y

M3 - Article

VL - 52

SP - 613

EP - 615

JO - Indian Pediatrics

JF - Indian Pediatrics

SN - 0019-6061

IS - 7

ER -